Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Pembrolizumab in Treating Patients with Stage III-IV High-Risk Melanoma Before and After Surgery

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
Melanoma
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
MK-3475, Pembrolizumab (MK-3475)
Davis, Elizabeth
National
Vanderbilt University
09-27-2019
Treatment
ECOGMELS1801
NCT03698019

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site. Nodal, satellite/in-transit metastasis, distant metastases or disease in a prior complete lymphadenectomy basin must have been confirmed histologically by hematoxylin (H) & eosin (E) stained slides.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: